Fecal microbiota transplant for treatment of clostridium difficile infection in immunocompromised patients

American Journal of Gastroenterology

Volumn 109, Issue 7, 2014, Pages 1065-1071

  Kelly, Colleen R ^a   Ihunnah, Chioma ^a   Fischer, Monika ^b   Khoruts, Alexander ^c   Surawicz, Christina ^d   Afzali, Anita ^d   Aroniadis, Olga ^e   Barto, Amy ^e   Borody, Thomas ^g   Giovanelli, Andrea ^h   Gordon, Shelley ⁱ   Gluck, Michael ^j   Hohmann, Elizabeth L ^k   Kao, Dina ^l   Kao, John Y ^m   McQuillen, Daniel P ^f   Mellow, Mark ⁿ   Rank, Kevin M ^c   Rao, Krishna ^m   Ray, Arnab ^o   Schwartz, Margot A ^j   Singh, Namita ^p   Stollman, Neil ^h   Suskind, David L ^p   Vindigni, Stephen M ^d   Youngster, Ilan ^k   Brandt, Lawrence ^e   more..

^a BROWN UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Centre for Digestive Diseases   (Australia)

^h Northern California Gastroenterology Associates   (United States)

ⁱ CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^j VIRGINIA MASON MEDICAL CENTER   (United States)

^k BOSTON CHILDREN S HOSPITAL   (United States)

^l UNIVERSITY OF ALBERTA   (Canada)

^m UNIVERSITY OF MICHIGAN   (United States)

ⁿ INTEGRIS BAPTIST MEDICAL CENTER   (United States)

^o OCHSNER CLINIC FOUNDATION   (United States)

^p SEATTLE CHILDREN S HOSPITAL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ADULT; AGED; ARTICLE; ASPIRATION PNEUMONIA; BLOATING; BRAIN DISEASE; CATHETER INFECTION; CLOSTRIDIUM DIFFICILE INFECTION; COLON RESECTION; COLONOSCOPY; DIARRHEA; DISEASE EXACERBATION; DISEASE SEVERITY; FECES MICROFLORA; FECES MICROFLORA TRANSPLANTATION; FEMALE; FEVER; FOLLOW UP; GASTROENTEROLOGICAL PROCEDURE; HIP PAIN; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATORY BOWEL DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NAUSEA AND VOMITING; NEOPLASM; NONHUMAN; PANCYTOPENIA; PATIENT SAFETY; PERTUSSIS; PRIORITY JOURNAL; RECURRENT DISEASE; RETROSPECTIVE STUDY; THERAPY EFFECT; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CLOSTRIDIUM DIFFICILE; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; MALE; MICROBIOTA; MIDDLE AGED; QUESTIONNAIRES; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84903894091     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2014.133     Document Type: Article

References (40)

1. Cohen SH, Gerding DN, Johnson S et al. Clinical Practice Guidelines for Clostridium dif cile Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol 2010;31: 431-55.
2. McDonald LC, Owings M, Jernigan DB. Clostridium dif cile infection in patients discharged from US short stay hospitals, 1996-2003. Emerg Infect Dis 2006;12:409-15.
3. King RN, Lager SL. Incidence of Clostridium dif cile infections in patients receiving antimicrobial and acid-suppression therapy. Pharmacotherapy 2011;31:642-8.
4. McFarland LV, Surawicz CM, Rubin M et al. R e c u r r e n t Clostridium dif cile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999;20:43-50.
5. McFarland LV. A lt er n ati ve t reat m en ts fo r Clostridium dif cile disease: what really works? J Med Microbiol 2005;54:101-11.
6. Eiseman B, Silen W, Bascom GS et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 1958;44:854.
7. Kassam Z, Lee CH, Yuan Y et al. Fecal microbiota transplantation for Clostridium dif cile infection: systematic review and meta-analysis. Am J Gastroenterol 2013;108:500-8.
8. VanNood E, Vrieze A, Nieuwdorp M et al. D u o d en al In fu sio n o f D o n o r Feces for Recurrent Clostridium dif cile. N Engl J Med 2013;368:407-15.
9. Dubberke ER, Burdette SE et al. Clostridium dif cile infections in solid organ transplantation. Am J Transplant 2013;13:42-9.
10. Munoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fun-gemia: an emerging infectious disease. Clin Infect Dis 2005;40:1625-34.
11. Surawicz CM, Brandt LJ, Binion DG et al. Guidelines for diagnosis, treatment, and prevention of Clostridium dif cile infections. Am J Gastroenterol 2013;108:478-98.
12. Bakken JS, Borody T, Brandt LJ et al. T reatin g Clostridium dif cile infection with fecal microbiota transplantation. Clin Gastroenterol Hepatol 2011;9:1044-9.
13. Kelly C, Brandt L. Fecal Transplant for Relapsing C. dif cile infection. Trial in progress. Accessed December 27, 2013 at: http://clinicaltrials.gov/ct2/ show/NCT01703494?term=FMT+providence&rank=1.
14. Friedman-Moraco RJ, Mehta AK, Lyon GM et al. Fecal microbiota transplantation for refractory Clostridium dif cile colitis in solid organ transplant recipients. Am J Transplant 2014;14:477-80.
15. Figueroa I, Johnson S, Sambol SP et al. Relapse versus reinfection: recurrent Clostridium dif cile infection following fdaxomicin or vancomycin. Clin Infect Dis 2012;55(Suppl 2): S104-9.
16. Louie TJ, Miller MA, Mullane KM et al. Fidaxomycin versus vancomycin for Clostridium dif cile infection. N Engl J Med 2011; 364: 422-31.
17. Sanchez TH, Brooks JT, Sullivan PS et al. Bacterial diarrhea in persons with HIV infection, United States, 1992-2002. Clin Infect Dis 2005; 41: 1621-7.
18. West M, Pirenne J, Chavers B et al. Clostridium dif cile colitis af er kidney and kidney pancreas transplantation. Clin Transplant 1999; 13: 318-23.
19. Gorschluter M, Glasmacher A, Hahn C et al. Clostridium dif cile infection in patients with neutropenia. Clin Infect Dis 2001;33:786-91.
20. Anand A, Glatt AE. Clostridium dif cile infection associated with antine-oplastic chemotherapy: a review. Clin Infect Dis 1993;17:109-13.
21. Bufe CG, Pamer EG. Microbiota-mediated colonization resistance against intestinal pathogens. Nat Rev Immunol 2013;13:790-801.
22. Kyne L, Warny M, Qamar A et al. Association between antibody response to toxin A and protection against recurrent Clostridium dif cile diarrhea. Lancet 2001;357:189-93.
23. Leav BA, Blair B, Leney M et al. Serum anti-toxin B antibody correlates with protection from recurrent Clostridium dif cile infection (CDI). Vaccine 2010;28:965-9.
24. Rodemann JF, Dubberke ER, Reske KA et al. Incidence of Clostridium dif-f cile infection in infammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44.
25. Binion DG. Clostridium dif cile infection in patients with inf ammatory bowel disease. Gastroenterol Hepatol (NY) 2012;8:615-7.
26. Ananthakrishnan AN, McGinley EL, Binion DG et al. A nationwide analysis of changes in severity and outcomes of inf ammatory bowel disease hospitalizations. J Gastrointest Surg 2011;15:267-76.
27. Ananthakrishnan AN, McGinley EL, Saeian K et al. Temporal trends in disease outcomes related to Clostridium dif cile infection in patients with infammatory bowel disease. Infamm Bowel Dis 2011;17:976-83.
28. Nguyen GC, Kaplan CG, Harris ML et al. A national survey of the prevalence and impact of Clostridium dif cile infection among hospitalized in-fammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50.
29. Jen MH, Saxena S, Bottle A et al. Increased health burden associated with Clostridium dif cile diarrhoea in patients with inf ammatory bowel disease. Aliment Pharmacol Ter 2011;33:1322-31.
30. Meyer AM, Ramzan NN, Lofus EV Jr et al. The diagnostic yield of stool pathogen studies during relapses of inf ammatory bowel disease. J Clin Gastroenterol 2004;38:772-5.
31. Schneeweiss S, Korzenik J, Solomon DH et al. I n f iximab and other immu-nomodulating drugs in patients with inf ammatory bowel disease and the risk of serious bacterial infections. Aliment Pharmacol Ter 2009;30: 253-64.
32. Das R, Feuerstadt P, Brandt LJ. Glucocorticoids are associated with increased risk of short-term mortality in hospitalized patients with clostridium difcile-associated disease. Am J Gastroenterol 2010;105: 2040-9.
33. DeLeon L, Watson J, Kelly C. transient f are of ulcerative colitis af er fecal microbiota transplantation for recurrent Clostridium dif cile infection. Clin Gastroenterol Hepatol 2013;11:1036-8.
34. Angelberger S, Reinisch W, Makristathis A et al. Temporal bacterial community dynamics vary among ulcerative colitis patients af er fecal micro-biota transplantation. Am J Gastroenterol 2013;108:1620-30.
35. Kump PK, Grochenig HP, Lackner S et al. Alteration of intestinal dysbiosis by fecal microbiota transplantation does not induce remission in patients with chronic active ulcerative colitis. Infamm Bowel Dis 2013;19: 2155-65.
36. Chang JY, Antonopoulos DA, Kalra A et al. Decreased diversity of the fecal microbiome in recurrent Clostridium dif cile associated diarrhea. J Infect Dis 2008;197:435-6.
37. Hamilton MJ, Weingarden AR et al. High-thoughput DNA sequence analysis reveals stable engraf ment of gut microbiota following transplantation of previously frozen fecal bacteria. Gut Microbes 2013;4:125-35.
38. Weingarden AR, Chen C, Bobr A et al. Microbiota transplantation restores normal fecal bile acid composition in recurrent clostridium dif cile infection. Am J Physiol Gastrointest Liver Physiol 2014; 306: G310-9.
39. Chow J, Tang H, Mazmanian SK. Pathobionts of the gastrointestinal micro-biota and infammatory disease. Curr Opin Immunol 2011;23:473-80.
40. Weingarden A, Hamilton M, Sadowsky M et al. R eso lu tio n o f severe Clostridium dif cile infection following sequential fecal microbiota transplantation. J Clin Gastroenterol 2013;47:735-7.